SK Inc. in Talks to Sell US CDMO Plant to Novo Nordisk

• SK Inc. is negotiating to sell its CDMO plant in Virginia, operated by SK Pharmteco, to Novo Nordisk for an estimated $216 million.

• The deal is expected to be completed by the end of August.

SK Inc., the holding and investment company of South Korea’s SK Group, is in the final stages of negotiations to sell a major asset of its contract drug-making unit, SK Pharmteco Co., to Novo Nordisk A/S. The asset in question is a contract development and manufacturing organization (CDMO) factory located in Petersburg, Virginia.

The deal, estimated to be worth 300 billion won ($216 million), is expected to be finalized by the end of August, according to sources familiar with the matter. This move aligns with SK Inc.’s strategic decisions regarding its CDMO operations in the United States.

SK Pharmteco operates several CDMO facilities across the US, including plants in California, Virginia, and Texas. The sale of the Virginia plant represents a significant transaction within the contract manufacturing sector.